FDA approves Gazyva for chronic lymphocytic leukemia

Author(s):

On Nov. 1, the U.S. Food and Drug Administration (FDA) approved Gazyva (obinutuzumab) for use in combination with chlorambucil to treat patients with previously untreated chronic lymphocytic leukemia. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here